Background: Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory illness considered a progressive joint injury and difficult to treat due to persistent synovitis. Patients suffer from swelling, and stiffness in many joints bilaterally. Objective: The purpose of this investigation is to the impact of medication on the levels of TNF-α and IL-17 in rheumatoid arthritis (RA) patients and to detect the differences in IL-17 and TNF-α levels in treated and untreated cases to determine the medication may affect these inflammatory markers in RA patients. Methodology: Seventy samples were collected from patients divided into (35 receive medicine and 35 without medicine) in the teaching Hospital of Alsadair. Thirty samples were collected from healthy people as control. The period of study between September 2023 to February 2024. RA was detected by clinical examination and laboratory investigations including anti-ccp, RF, serum interleukin-17 and TNF-α level. Results: This research revealed 20 (29.4%) women and 5 (54.5%) men. This study illustrated that patients without medicine gave a positive result for RF, while patients receive medicine had negative results compared with control had negative result (p < 0.01). Also the study showed that positive results for Anticcp in patients without medicine, while patients taking medicine were 31(88.5%) who showed a negative result for anticcp compare with control 30 (100%) (p < 0.01). Low levels of IL-17 and TNF (3.7±0.7and 2.4. ±0.04) respectively were detected in patients taking medicine compared with controls, while the elevated IL-17 levels and TNF appeared in patients without medicine (IL-17, 5.6± 0.23 and TNF 4.1±0.01) respectively (p-value < 0.05) compared with control. High amounts of IL-17 and TNF in patients with chemical treatment were (4.3±0.9 and 4.1±0.02) in contrast to the control respectively, also biological treatment indicates no significant difference in levels of IL-17 and TNF (3.1±0.01 and 2.2±0.01respectively). In addition, patients taking combination therapy did not show a noticeable change in IL-17(3.3±0.1) and TNF (2.1±0.01). Conclusion: RA affects women more than men, IL-17, and TNF-α can be used as diagnostic biomarkers and Anti-CCP is a better diagnostic guide due to their higher sensitivity and specificity for RA.